Qiagen N.V. (QIA):企業の財務及び戦略的SWOT分析

GlobalDataが発行した調査報告書(GDME2456FSA)
◆英語タイトル:Qiagen N.V. (QIA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME2456FSA
◆発行会社(リサーチ会社):GlobalData
◆発行日:2016年2月16日
◆ページ数:74
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オランダ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥14,125見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD375 ⇒換算¥42,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Qiagen N.V. (QIA) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Qiagen N.V. (Qiagen) is a healthcare company. It provides extensive products and services such as automated solutions, isolation analysis, data interpretation systems, reagents,accessories and labware, and sample and assay technologies to study the molecular information of biological material. Its sample technologies help isolate and process proteins, DNA and RNA from biological samples such as blood or tissue; and assay technologies facilitate the development of isolated biomolecules such as the DNA of a specific virus for later analysis. The company has over 500 products that include consumable products, automated solutions for sample collection, and nucleic acid and protein handling, separation, and purification, besides open and target specific assays. Qiagen also supplies diagnostic test kits and assays for human and veterinary molecular diagnostics. The company caters to animal pathogens and genotyping, cancer research, drug development, environmental water testing, human identity & forensic testing, microbiology research, among other areas. The company operates in more than 100 countries and sells its products to pharmaceutical and biotechnology companies and research institutions. Qiagen is headquartered in Venlo, the Netherlands.

The company intends to enter into Next Generation Sequencing market. To this end, it is developing next-generation benchtop sequencer with its subsidiary, Intelligent Bio-Systems, Inc.

Qiagen N.V. Key Recent Developments

Feb 11, 2016: QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing
Feb 02, 2016: QIAGEN Reports Results for Fourth Quarter and Full-Year 2015
Feb 02, 2016: New agreements underscore QIAGEN’s leadership in bioinformatics
Jan 10, 2016: QIAGEN Announces Preliminary Results for Full-Year 2015 and Provides 2016 Outlook
Nov 02, 2015: QIAGEN Expands Clinical Decision Support for NGS in Oncology Labs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 – About the Company 6
Qiagen N.V. – Key Facts 6
Qiagen N.V. – Key Employees 7
Qiagen N.V. – Key Employee Biographies 8
Qiagen N.V. – Major Products and Services 9
Qiagen N.V. – Medical Equipment Pipeline Products Data 11
Qiagen N.V. Pipeline Products by Equipment Type 11
Qiagen N.V. Pipeline Products by Development Stage 16
Qiagen N.V. – History 20
Qiagen N.V. – Company Statement 28
Qiagen N.V. – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Qiagen N.V. – Key Manufacturing Facilities 32
Joint Venture 32
Section 2 – Company Analysis 33
Qiagen N.V. – Business Description 33
Qiagen N.V. – Corporate Strategy 35
Qiagen N.V. – SWOT Analysis 36
SWOT Analysis – Overview 36
Qiagen N.V. – Strengths 36
Strength – Established Presence in Molecular Diagnostics Market 36
Strength – Success in International Markets 36
Strength – Strong Research and Development Activities 36
Strength – Improving Financial Position 36
Qiagen N.V. – Weaknesses 37
Weakness – Substantial Debt 37
Weakness – Patent Infringement Concerns 37
Qiagen N.V. – Opportunities 38
Opportunity – Global In-Vitro Diagnostics Market 38
Opportunity – Growth in E7 markets 38
Opportunity – Expansion through Acquisitions 38
Qiagen N.V. – Threats 39
Threat – Intense Competition 39
Threat – Stringent Government Regulations 39
Threat – Integration of Acquisitions 39
Qiagen N.V. – Key Competitors 40
Section 3 – Company Financial Ratios 41
Financial Ratios – Capital Market Ratios 41
Financial Ratios – Annual Ratios 42
Performance Chart 44
Financial Performance 44
Financial Ratios – Interim Ratios 45
Financial Ratios – Ratio Charts 46
Section 4 – Company’s Lifesciences Financial Deals and Alliances 47
Qiagen N.V., Medical Equipment, Deals By Year, 2010 to YTD 2016 47
Qiagen N.V., Medical Equipment, Deals By Type, 2010 to YTD 2016 48
Qiagen N.V., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 49
Qiagen N.V., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 50
Qiagen N.V., Recent Deals Summary 51
Section 5 – Company’s Recent Developments 52
Feb 03, 2016: QIAGEN’s Investigator human identity testing products meet new ISO standard 52
Feb 02, 2016: QIAGEN Reports Results for Fourth Quarter and Full-Year 2015 53
Feb 02, 2016: New agreements underscore QIAGEN’s leadership in bioinformatics 57
Jan 26, 2016: QIAGEN to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage 58
Jan 10, 2016: QIAGEN Announces Preliminary Results for Full-Year 2015 and Provides 2016 Outlook 59
Dec 01, 2015: QIAGEN’s QuantiFERON-TB test chosen for use in England tender 60
Nov 04, 2015: QIAGEN introduces GeneReader NGS System 61
Nov 04, 2015: Evaluation confirms: QIAGEN’s new GeneReader NGS System delivers valuable clinical insights 63
Nov 02, 2015: QIAGEN Expands Clinical Decision Support for NGS in Oncology Labs 64
Oct 28, 2015: Qiagen Reports Results For Third Quarter And First Nine Months Of 2015 65
Section 6 – Appendix 70
Methodology 70
Ratio Definitions 70
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Qiagen N.V., Key Facts 6
Qiagen N.V., Key Employees 7
Qiagen N.V., Key Employee Biographies 8
Qiagen N.V., Major Products and Services 9
Qiagen N.V. Number of Pipeline Products by Equipment Type 11
Qiagen N.V. Pipeline Products by Equipment Type 12
Qiagen N.V. Number of Pipeline Products by Development Stage 16
Qiagen N.V. Pipeline Products by Development Stage 17
Qiagen N.V., History 20
Qiagen N.V., Subsidiaries 29
Qiagen N.V., Key Manufacturing Facilities 32
Qiagen N.V., Joint Venture 32
Qiagen N.V., Key Competitors 40
Qiagen N.V., Ratios based on current share price 41
Qiagen N.V., Annual Ratios 42
Qiagen N.V., Interim Ratios 45
Qiagen N.V., Medical Equipment, Deals By Year, 2010 to YTD 2016 47
Qiagen N.V., Medical Equipment, Deals By Type, 2010 to YTD 2016 48
Qiagen N.V., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 49
Qiagen N.V., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 50
Qiagen N.V., Recent Deals Summary 51
Currency Codes 70
Capital Market Ratios 70
Equity Ratios 71
Profitability Ratios 71
Cost Ratios 72
Liquidity Ratios 72
Leverage Ratios 73
Efficiency Ratios 73

List of Figures
Qiagen N.V. Pipeline Products by Equipment Type 11
Qiagen N.V. Pipeline Products by Development Stage 16
Qiagen N.V., Performance Chart (2010 - 2014) 44
Qiagen N.V., Ratio Charts 46
Qiagen N.V., Medical Equipment, Deals By Year, 2010 to YTD 2016 47
Qiagen N.V., Medical Equipment, Deals by Type, 2010 to YTD 2016 48
Qiagen N.V., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 49
Qiagen N.V., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 50

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Qiagen N.V. (QIA):企業の財務及び戦略的SWOT分析(Qiagen N.V. (QIA) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆